VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript

And in the PALISADE-2 study similar in PALISADE-1 similar safety profile although even less prevalent in terms of the treatment emergent adverse effects. So these are events. These data overall non-clinical and clinical really continue to reinforce our belief in why we don’t see these safety concerns you typically see associated with benzones or antidepressants. These are not systemically absorbed drugs. You cannot detect them in the plasma. And so you’re basically using the nose as a portal to achieve the effects from different regions of the brain that are associated with these different indications, not having to go in the mouth and might be metabolized by the liver, bump into other drugs through the bloodstream, other blood-brain barrier into the brain, all those are major factors that really distinguish this class from everything that’s historically been approved or is even in development for these neuropsychiatric indications.

So it’s not a concern we’ve had in the past, it’s not a concern the FDA had when we showed them the data and it’s certainly not a concern that we have now after tens of thousands of more doses and hundreds of more subjects since we first got that read from the FDA.

Tim Lugo: That’s great to hear. Thank you.

Operator: We have no further questions in the queue at this time. I would now like to turn the call back over to today’s speakers for any additional or closing remarks.

Mark McPartland: Thank you, operator. If there are any additional questions that you might have please don’t hesitate to contact us here Vistagen at ir@vistagen.com or contact me those listed on our press release issued earlier today as we noted, or on the contact section of our website. We also encourage you to register for email updates on our website to stay connected with the latest news from Vistagen. Again thank you for participating on the call today. We appreciate everyone’s attention and continued support and look forward to keeping you current on our continued progress. This concludes the call. Have a tremendous day.

Operator: This does conclude today’s program. Thank you for your participation. You may disconnect at any time.